Loading
Life sciences · Journal article
Extracellular Vesicles and Circulating Nucleic Acids · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Migrasomes are a newly identified class of extracellular vesicles (EVs) with a distinctive pomegranate-like morphology that are generated specifically from migrating cells. They are increasingly recognized as critically important mediators of intercellular communication involved in diverse physiological and pathological processes. However, their roles in cancers remain incompletely defined, and a consensus on migrasome-mediated malignant phenotypes is still lacking. In this review, we first summarize the current knowledge of migrasome biogenesis, distribution, and isolation methodologies. We then systematically discuss the multifaceted roles of migrasomes within the tumor microenvironment (TME), with particular emphasis on their contribution to cancer metastasis, progression and drug resistance. Furthermore, we explore the potential clinical applications of migrasomes in cancer diagnosis and therapy, and outline the key challenges and controversies that hinder their translation into clinical practice. Overall, this review provides an updated perspective on the roles of migrasomes in cancer biology and highlights the emerging opportunities for migrasome-informed targeted therapeutics.